Despite recent advances in its diagnosis and treatment, prostate cancer remains a major cause of cancer death. The dire outcome for men diagnosed with advanced prostate cancer, and particularly castration-resistant disease, warrants focused analyses linking laboratory and clinical studies to elucidate molecular pathways of advanced disease and identify new targets for directed therapies. Participants will discuss current targets, including the androgen receptor and components of the Pten/Akt/mTOR and Erk MAP kinase signaling pathways, as well as, introduce strategies for identifying new targets, and for investigating the efficacy of such targets for clinical intervention. Participants will discuss potential immunologic targets, immunotherapeutic strategies, and an understanding of the mechanisms of immune tolerance in prostate cancer. Participants will discuss strategies to evaluate target suitability in preclinical models, as well as, the translation of such studies to clinical trials.
New Concepts in Organ Site Research: Emerging Biological Observations in Prostate Cancer and Their Translation

Senescence therapy for prostate cancer; Pier Paolo Pandolfi. Beth Israel Deaconess Medical Center, Boston, MA

Immunotherapeutic strategies in prostate cancer; Eric J. Small. UCSF-Mt. Zion Cancer Ctr., San Francisco, CA

Preclinical analyses of hormone refractory prostate cancer; Cory Abate-Shen. Herbert Irving Comprehensive Cancer Center, New York, NY

The inflammatory component of prostate cancer: From mouse to man and back again; Charles G. Drake. Johns Hopkins Univ., Baltimore, MD,